Farah Rahman, MD, MPH, highlights a pilot study on the use of wearable biofeedback technology to better understand and address burnout among urology residents. Sudha Jayaraman, MD, MSc, FACS, recaps a ...

Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years. Nogapendekin alfa inbakicept ...

A recap of the FDA submissions and regulatory decisions in urology from September 2026. Welcome to Urology Times’® monthly FDA update! This month’s regulatory news featured new and expanded treatment ...

Eligibility required PSA-defined recurrence plus aggressive pathology (eg, Gleason 8–10, pT3b, pN1, persistent PSA, or PSA ≥0.7), yielding a cohort with frequent multi-feature high-risk disease.

PACE-A randomized surgery-eligible cT1c–T2c, Gleason ≤3+4, PSA ≤20 ng/mL patients to prostatectomy versus 5-fraction SBRT without ADT, enabling direct efficacy and toxicity comparisons.